Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function

BACKGROUND: Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib versus sorafenib in patients with uHCC who deteriorated to Child-Pugh class B (CP-B) on treatment. METHODS: We retrospectively evaluated pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Jasmine, Cho, May Thet, Kim, Edward Jae-Hoon, Ren, Min, Ramji, Zahra, Vogel, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425881/
https://www.ncbi.nlm.nih.gov/pubmed/36051472
http://dx.doi.org/10.1177/17588359221116608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425881/
https://www.ncbi.nlm.nih.gov/pubmed/36051472
http://dx.doi.org/10.1177/17588359221116608

Ejemplares similares